Zimbabwe has turned down a substantial American healthcare agreement worth $367m (£272m) over five years due to the United States' insistence on confidential data.
The decision was revealed after a government memo from December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
A government spokesperson has since stated that the United States was demanding access to genetic material for research and profit while refused to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for continued dialogue to reach a deal agreeable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a court blocked a related deal with the US after legal challenges were raised about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its spending was "inefficient" and his government was seeking direct bilateral deals to enhance openness and accountability.
Based on reports, Sixteen nations in Africa have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Declined Agreement
This assistance for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, with no equivalent promise of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Effectively, our nation would supply the basic resources for medical research without any assurance that the end products would be accessible to our population should a future health crisis emerge."
National Interest and Global Health
He also said that the American exit from the global health body and its push of bilateral health agreements were undermining structures already set up via the international organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with future pandemics.
"This mechanism is intended to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as hostility towards the US," he added.
"We are open to further discussions with our American counterparts on how future collaboration could be structured in a way that honours the independence and interests of each country."
Medical Community Response
A leading public health body expressed it acknowledged the government's concerns, but recommended that talks must proceed given that much of the country's Aids initiatives depended on international support.
"If technical issues exist, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group added.
This impasse emphasises the complex debate between receiving crucial foreign assistance and protecting local interests in an increasingly data-driven world.